New drug cocktail shows promise against aggressive lung cancer
NCT ID NCT04728230
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times
Summary
This study tests a new treatment combination for people with extensive-stage small cell lung cancer (ES-SCLC) who haven't had treatment yet. It combines a PARP inhibitor (olaparib), an immunotherapy drug (durvalumab), standard chemotherapy (carboplatin and etoposide), and radiation. The goal is to see if this mix is safe and works better than current options at controlling the cancer. About 63 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IV LUNG CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.